Gleize

This trial enrolls participants from previous studies evaluating adagrasib either alone or combined with other cancer therapies in patients with non-small cell lung cancer, colorectal cancer, and other advanced solid tumors. It is an open-label continuation study designed to provide long-term treatment for cancer patients who have already participated in those parent trials. The study is sponsored by Mirati Therapeutics Inc. and focuses on treatment of solid tumors. Participants receive adagrasib and may also receive other cancer drugs such as pembrolizumab, cetuximab, pemetrexed, docetaxel, irinotecan, leucovorin, oxaliplatin, and fluorouracil. The dosing and schedule are specified but depend on the parent study protocols. This trial includes multiple experimental arms reflecting different treatment combinations or regimens, continuing treatment for eligible patients who showed clinical benefit in the parent studies. During the study, participants are monitored for adverse events up to 90 days after their last dose or if they discontinue treatment. Researchers track serious adverse events, treatment-related discontinuations, and deaths related to adverse events. Participation involves ongoing treatment and safety assessments, with the study lasting until the primary completion date in February 2028. The study does not include healthy volunteers and involves adults aged 18 years and older.

Researchers are evaluating the effectiveness and safety of a combination treatment including BMS-986489 a fixed dose combination of BMS-986012 and Nivolumab with Carboplatin plus Etoposide compared to Atezolizumab combined with Carboplatin plus Etoposide as a first-line therapy for participants with extensive-stage small cell lung cancer. This is a randomized, double-blind, multicenter phase 3 trial sponsored by Bristol-Myers Squibb. Participants will receive either the experimental combination of BMS-986489 with Carboplatin and Etoposide or the comparator regimen of Atezolizumab with Carboplatin and Etoposide. Doses are given on specified days according to the study protocol. The study examines these treatments as initial therapy for this type of lung cancer. During the trial, participants will be closely monitored for overall survival over a period of up to 5 years. Researchers will also measure other outcomes such as time to clinical decline based on lung cancer symptom scores, response duration, progression-free survival, and the occurrence of adverse events up to 135 days after the last treatment. Regular assessments will include imaging and clinical evaluations to track treatment effects and safety throughout the study.

Researchers are evaluating the effectiveness and safety of lorlatinib in patients with untreated ALK-positive non-small-cell lung carcinoma NSCLC in a real-world French context. This study, sponsored by Pfizer, focuses on adults aged 18 years and older who have locally advanced or metastatic ALK-positive NSCLC confirmed by specific diagnostic tests. The goal is to understand how lorlatinib works and its safety profile outside of controlled clinical trial settings. Participants in this study receive lorlatinib as a single agent at a dose of 100 mg taken orally once daily without interruption. The treatment continues as per routine care, and patients undergo thorough radiological evaluations including contrast-enhanced CT scans of the thorax and upper abdomen, as well as brain MRI, before starting lorlatinib. The study monitors various outcomes such as progression-free survival, overall survival, response rates, duration of response, and adverse events over a period of up to 48 months. Throughout the study, participants will have scheduled assessments at regular intervals including clinical evaluations, imaging studies, and questionnaires to track symptoms, treatment adherence, and quality of life. Researchers will also monitor for specific side effects, treatment resistance mechanisms, and changes in patient-reported outcomes related to central nervous system toxicity and overall health status. The total duration of participation includes follow-up visits lasting up to 48 months to gather long-term data on treatment effects and safety.

Researchers are evaluating the diagnostic effectiveness and cost efficiency of using connected watch ECG monitoring compared to the conventional 48-hour external Holter ECG for patients experiencing palpitations without documented electrocardiographic traces. Palpitations are a common reason for emergency consultations, but their transient and infrequent nature makes diagnosis challenging. This study aims to compare how well these two strategies identify the cause of arrhythmias six months after cardiological consultation. All participants will wear a standard 48-hour Holter ECG monitor and also receive a connected watch for a six-month period. They will be instructed to record ECG tracings with the connected watch only when experiencing symptoms. The Holter ECG records continuously for 48 hours, while the watch provides extended monitoring and allows up to three symptom-triggered ECG transmissions. Participants will be supported in using the watch and the associated Health Mate app and contacted two months into the study to assess understanding, compliance, and any adverse events. During the study, participants will complete event forms and transmit ECG recordings when symptomatic. Researchers will evaluate the rate at which the connected watch identifies arrhythmias compared to the Holter ECG, along with types of diagnoses and the time healthcare professionals spend per diagnosis. The primary outcome is measured at six months or when the watch is returned. The study includes follow-up calls and data collection on diagnosis rates and medical time to assess the cost-effectiveness of the connected watch strategy.

Researchers are evaluating a patient-centered Clinical Decision Support System CDSS called Lianeli to help primary care professionals identify patients eligible for recommended health screenings based on guidelines from the French National Authority for Health HAS. The study aims to improve shared decision-making between doctors and patients, address obstacles like lack of time and information, and reduce patient decision-making conflicts during preventive care consultations. The Lianeli platform is used first by patients through a health self-questionnaire and access to information sheets, then jointly by patients and their general practitioners during a prevention-focused consultation. This system matches individual patient data with national screening recommendations to suggest appropriate tests. The study uses a mixed approach including quantitative assessments of Lianelis use and qualitative interviews with patients and healthcare professionals to explore feasibility and satisfaction. Participants will complete questionnaires and take part in consultations using the Lianeli system, with follow-up assessments within 30 to 60 days after inclusion. Researchers will measure how fully Lianeli is used, patient and professional satisfaction, usability, and screening uptake. Interviews and focus groups will explore implementation factors. The total participation includes initial consultations, questionnaire completion, and follow-up evaluations to understand the impact of the CDSS in primary care prevention.

Researchers are evaluating the long-term safety of two different dose regimens of tozorakimab in people with Chronic Obstructive Pulmonary Disease COPD who have a history of exacerbations. This Phase III, multicenter, open-label extension study includes participants who have already completed earlier related studies. The aim is to better understand how these treatments perform over an extended period. Participants receive tozorakimab through subcutaneous injections using pre-filled syringes. The study compares two dosing regimens, with participants continuing treatment from predecessor studies such as MIRANDA, TITANIA, or PROSPERO. This chronic dosing extension allows researchers to observe safety over a long timeframe. During the study, participants will have regular assessments to monitor adverse events and overall health status for up to 2 to 3 years. Researchers will collect safety data, including any side effects, to evaluate tolerability. Participants must provide informed consent and follow study procedures while being monitored closely throughout the trial period, which lasts until late 2028.

Type I interferonopathies are rare genetic disorders causing inflammation and affecting mainly the central nervous system, with common joint problems and occasional blood or immune system issues. These diseases often begin in childhood but can also start in adulthood and are resistant to usual immunosuppressive treatments. Researchers aim to better understand how these conditions develop over time in both children and adults to identify diagnostic and monitoring biomarkers and improve future therapies. This observational study includes patients with genetically confirmed type I interferonopathy who are part of a social security system. The study will follow patients from 2025 to 2045, collecting information to characterize disease progression, identify genotype-related immune factors, discover biomarkers for diagnosis and prognosis, and monitor treatment responses based on patient phenotypes and genotypes. Participants will be observed over many years with regular assessments to track how their condition changes and how they respond to treatments. The main focus is on understanding the natural history of the disease by reviewing clinical features, biological markers, and genetic information. This long-term follow-up will help researchers define patient subgroups and guide more personalized treatment approaches in the future.

This research aims to observe patients in France with HER2-negative early breast cancer who are treated with olaparib, a medication chosen by their doctors. The study focuses on understanding how often patients complete the full course of olaparib treatment and gathers information on related genetic factors and medical history. It is a national, multicenter, prospective observational study without experimental treatment assignment. Participants in this study receive adjuvant olaparib treatment as part of their usual care under their physicians discretion. The study does not assign treatments but follows patients who start olaparib, tracking their treatment progress for up to 18 months after inclusion. There are no additional interventions or placebo groups. Throughout the study, researchers collect data on treatment completion rates, types of BRCA mutations, variant types, medical history, and the time until olaparib treatment stops. Participation involves observational follow-up, with no extra treatment visits beyond routine care. The overall participation lasts 18 months after a patients enrollment, focusing on real-world treatment experiences and outcomes.